Immunotherapy for recurrent head and neck cancer
Part of Cancer clinical trials.
This trial tests a drug called anti-PD-1 (an immunotherapy that helps your immune system attack cancer) for people whose head and neck cancer has returned or spread but can still be removed with surgery. The goal is to see if this treatment helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have head and neck cancer (not nasopharyngeal cancer) that has come back or spread, and it can be removed with surgery.
- You have already had surgery and/or radiation therapy.
- You are in good enough health to have surgery and receive immunotherapy (a type of treatment that helps your immune system fight cancer).
- You have not had immunotherapy before (like anti-PD-1).
- You are willing to have surgery and receive the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
Hear when a new Recurrent Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.